Background and Aims: Primary sclerosing cholangitis [PSC] is an idiopathic chronic disorder of the hepatobiliary system associated with inflammatory bowel disease [IBD], mainly ulcerative colitis [UC]. Colitis in patients with PSC and UC [PSC-UC] exhibits characteristic features and is linked to increased colon cancer risk. Genetic studies have identified immune-related susceptibility genes that only partially overlap with those involved in IBD. These observations suggest that PSC-UC may represent a distinct form of IBD. It remains to be elucidated whether different immune mechanisms are involved in colitis in these patients. We aimed to evaluate systemic and intestinal T cell and innate lymphoid cell [ILC] responses, previously associated with IBD, in patients with PSC-UC compared with patients with UC and healthy controls. Methods: Blood samples and colorectal biopsies were collected from patients with PSC-UC, patients with UC, and healthy controls. T cell and ILC phenotypes were analysed by multicolour flow cytometry.
Introduction
Primary sclerosing cholangitis [PSC] is a chronic progressive disorder of the hepatobiliary system characterised by inflammation, fibrosis, and stricturing of the intrahepatic and extrahepatic bile ducts, leading to liver cirrhosis. There is no cure for PSC and prognosis remains poor. PSC is associated with inflammatory bowel disease [IBD] in 60-80% of patients, among whom 80% are diagnosed with ulcerative colitis [UC] and the remaining with Crohn's disease [CD] or indeterminate colitis. 1 However, multiple studies have suggested that the clinical manifestations of PSC-UC differ from those of UC.
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In particular, PSC-UC has been reported more frequently to have a quiescent course, extensive or right-sided colitis, patchy inflammation, backwash ileitis, and higher occurrence of pouchitis after colectomy. 2, 3 Furthermore, patients with PSC-UC have a 5-fold increased risk to develop colorectal cancer compared with those with UC, and patients with PSC are also at increased risk of hepatobiliary malignancies, particularly cholangiocarcinoma [cumulative lifetime incidence 10-30%] and gallbladder adenoma, dysplasia, or carcinoma. [4] [5] [6] As with IBD, the pathogenesis of PSC is unknown. The two main theories─which are not mutually exclusive─implicate an aberrant homing of gut-derived memory T cells to the liver, and bacterial translocation secondary to increased intestinal permeability ['leaky gut' hypothesis]. 7, 8 Against the latter theory, however, intestinal inflammation is usually mild in these patients. More recently a PSC microbiota hypothesis has been proposed, which suggests that intestinal dysbiosis may play a central role. 9, 10 Genetic studies have identified 23 loci associated with disease susceptibility, with genome-wide significance and other suggestive associations. [11] [12] [13] [14] [15] [16] Most of these genes encode for proteins involved in immune functions and have been implicated in other immunemediated disorders, not only IBD but also type I diabetes, coeliac disease, and rheumatoid arthritis. In particular, the strong human leukocyte antigen [HLA] association suggests that antigen-driven adaptive immune responses, possibly mediated by CD4 + T cells, may contribute to disease pathogenesis. 11 The observation that only a minority of these variants are associated with IBD is surprising, considering the high concomitance of PSC and IBD, as well as the higher numbers of cases and 10 times more risk loci identified in the IBD genome-wide association studies. 17, 18 Distinct clinical manifestations and moderate genetic overlap indicate that PSC-associated IBD represents a unique form of IBD. 2 However, the immunopathogenesis of intestinal inflammation in PSC-UC has not been fully investigated, and it remains unknown whether PSC-UC and UC are immunologically different.
We hypothesised that different lymphocyte populations may be recruited from the circulation to the colon─and potentially to the liver─to mediate inflammation and inflammation-associated cancer in patients with PSC-UC.
We analysed T cell and innate lymphoid cell [ILC] responses, previously associated with IBD, in the systemic and intestinal immune response in patients with PSC-UC compared with patients with UC and non-inflammatory controls. Increased Th1 and Th17 responses have been described in IBD patients with both CD and UC phenotypes; however, the role of increased Th1 and Th17 responses in PSC-UC has not been fully investigated. 19 ILC are a population of lymphocytes that are enriched at mucosal sites, where they contribute to the immune response against pathogens but have also been implicated in the pathogenesis of intestinal inflammation and colitis-associated cancer in animal models. 20, 21 Several subsets of ILC reflecting functional characteristics of Th subsets have been described: T-bet + ILC1 secrete IFN-γ, GATA3 + ILC2 secrete IL-5 and IL-13 and RORγ-t + ILC3 secrete IL-17 and IL-22. 22 Recent evidence from animal models suggests that ILC can also modulate T cell activation and proliferation through IL-2-and MHC class II-dependent interactions.
23,24 Interestingly, we previously described an accumulation of IL-23 responsive ILC in the inflamed intestine of patients with CD, but not UC. 25 In this study, we observed distinct chemokine receptor (CCR) profiles on circulating T cells, confirming that specific changes in T cell trafficking properties are involved in the pathogenesis of intestinal and liver inflammation in patients with PSC-UC. Furthermore, ILC accumulation and increased Th1 responses were found in the colon of these patients, where they may contribute to inflammation and increased cancer risk. Altogether our data show that PSC-UC represents an immunological disease distinct from UC.
Materials and Methods

Study subjects
All patients and controls were recruited from the Translational Gastroenterology Unit [TGU] 
Cell isolation
PBMC were isolated using density centrifugation over Ficoll. Briefly, peripheral blood was diluted in an equal volume of PBS and centrifuged over a Ficoll-Hypaque layer at 2000 rpm for 20 min. Cells were collected at the Ficoll-plasma interface and washed in PBS. Lamina propria mononuclear cells [LPMC] were isolated from up to 10 biopsies using a combined mechanical and enzymatic digestion. 27 In brief, biopsies were incubated in 1 mM DTT solution in HBSS without calcium and magnesium at room temperature on a shaker for 15 min to remove adherent mucus. After three washes, biopsies were transferred in a gentleMACS tube [Miltenyi Biotech] with 5 ml of 1 mg/ml collagenase A [Roche]/DNase solution and shaken on a gentleMACS dissociator. Samples were shaken at 37°C for 1 h and further homogenised on the gentleMACS dissociator. The digested tissue was then filtered and washed in Hanks' balanced salt solution. 
Cell surface and intracellular FACS characterisation
Results
Patients' characteristics
The characteristics of patients and the numbers of intestinal and blood samples included in this study are shown in Table 1 .
There were no significant differences between UC and PSC-UC patient groups in terms of gender distribution, age, or treatment. Disease duration was similar in the two groups. The majority of PSC-UC patients presented large-duct PSC. Four blood samples and two colonic samples from four patients with small-duct [SD]-PSC-UC were also included in the analysis; 22% of PSC-UC patients had hyperbilirubinaemia. Only one patient had liver cirrhosis, as suggested by radiological tests [ultrasound or MRI] and confirmed at histological examination of liver biopsy [fibrosis staging 6/6]. As expected, a larger proportion of PSC-UC patients had extensive colitis and previous colectomy compared with UC patients. Colitis endoscopic activity was measured by the Ulcerative Colitis Endoscopic Index of Severity [UCEIS], 26 which was comparable in the subgroups of patients with UC and PSC-UC from which biopsies were obtained. All intestinal samples presented quiescent or mild to moderate inflammation at microscopic examination. At time of sample collection, patients were receiving medical treatment as stated in Table 1 . Figure 1A , B]. A significant reduction in the frequency of CCR9
+ cells was also observed in patients with UC and a similar trend was found in patients with PSC-UC, suggesting that CCR9 may also be involved in the migration of CD4 + T cells to the intestine and to the liver in these patients. Interestingly, the frequency of CCR4
+ cells was exclusively increased in patients with UC compared with controls. A similar increase in the frequency of CCR6 + cells was found in patients with UC and PSC-UC compared with controls. No difference was observed in the frequency of CCR10 + and CXCR3
+ cells between patients and controls [ Figure 1A , B]. Human Th-subsets are characterised by distinct CCR expression profiles. 28 We analysed the frequency of CCR6 + T cells in patients with PSC-UC, UC, and healthy controls. We observed decreased frequency of Th1 cells in patients with PSC-UC and increased frequency of Th2 cells in patients with UC, whereas increased frequencies of Th17 were found in both patient groups compared with controls [ Figure 2A , B].
In the memory CD8 + T cell compartment, we observed a reduction of the β7 + cells in patients with UC only. Figure 3A , B]. Figure 4A , B]. These data suggest that Th1 responses may contribute to intestinal inflammation in patients with PSC-UC.
3.5. Innate lymphoid cells are reduced in the peripheral blood and accumulate in the colon of patients with PSC-UC
We analysed the frequency of ILC among lymphocytes in peripheral blood and observed a trend towards a reduction in the frequency of ineage -CD127 + ILC in peripheral blood of patients with PSC-UC compared with controls [ Figure 5A , B, P = 0.05]. We characterised the frequency of c-KIT -
CRTH2
-ILC1, CRTH2 + ILC2 and c-KIT + CRTH2 -ILC3 cells among total ILC, and found a reduced proportion of ILC1 and increased frequency of ILC2 in the peripheral blood of patients with PSC-UC compared with controls, with a similar trend in patients with UC [ Figure 5C , D]. Interestingly, we observed an increased frequency of lineage -
CD127
+ ILC in the colon of patients with PSC-UC compared with patients with UC and with controls [ Figure 6A , B]. These data suggest that ILC may contribute to colonic inflammation and increased risk of cancer in PSC-UC.
Discussion
It has long been debated whether PSC-associated IBD should be considered a distinct form of IBD. Colitis in PSC has classically been related to that in UC, even if it has become clear that the clinical phenotype of colitis in PSC is unique. It is usually characterised by an indolent course of pancolitis or right-sided disease, with more frequent rectal sparing and backwash ileitis, higher incidence of pouchitis after colectomy, and a 5-fold increased risk of colorectal cancer compared with patients with UC.
Results of genetic studies have shown only partial overlap in the genetic susceptibility risks between PSC and IBD, supporting the hypothesis that these two diseases may represent distinct immunological disorders. More recently, the analysis of the intestinal microbiota has also identified specific gut microbial signatures in PSC compared with patients with UC and with healthy controls, again distinguishing patients with PSC [with or without IBD] from patients with UC. 9, 10 Altogether, this line of evidence indicates that intestinal inflammation in PSC may be pathogenetically different from that in UC. However, only a very limited number of studies have attempted to analyse the intestinal immune response in PSC-associated IBD. 29, 30 Therefore, it remains to be elucidated whether the immunological mechanisms involved in intestinal inflammation in PSC-associated colitis differ from those involved in IBD and more specifically UC. In this study, we investigated the systemic and intestinal immune response in patients with PSC-UC compared with patients with UC only and with healthy controls.
Macroscopic and microscopic intestinal inflammation was comparable in those patients from whom biopsies were obtained and the mucosal immune response was analysed.
The CCR profiling of peripheral memory T cells confirmed a role for the α4β7 integrin and CCR9 in the migration of T cells to the inflamed colon-and possibly to the liver-in patients with PSC-UC. In fact, previous studies have shown that the respective ligands, MAdCAM-1 and CCL25, normally expressed on the intestinal mucosal vessels, are ectopically expressed in the liver in PSC, and 20% of liver-infiltrating lymphocytes express CCR9 and α4β7. 7 We observed an increased frequency of CCR4 + CD4 + and CD8 + T cells in UC, but not in PSC-UC, compared with healthy controls. On the other hand, CCR6 + CD4 + T cells were increased in both patient groups compared with controls. Th2 responses mediate protection from parasites, but are also implicated in allergic reactions. Overactive atypical Th2 responses were originally described in UC, but subsequent studies have challenged the notion that UC is a Th2-driven disease. 19 Our Th-subset analysis based on CCR profiling showed increased frequency of CCR6 Th1/Th17 cells has been described which express both T-bet and RORγ, produce IL-17 and IFN-γ, and may play a pathogenic role in IBD. [31] [32] [33] [34] [35] Increased Th17 responses are found in IBD and have also been associated with liver inflammation and PSC. 19, 36 The frequency of circulating CCR6 + CCR4 + CXCR3 -Th17 cells was higher in both patients with PSC-UC and those with UC only compared with controls, whereas no differences were observed in the Th1/Th17 subset. No difference was found in IL-17 or IL-22 secretion by systemic T cells after stimulation.
The discrepancy observed between systemic T cell subsets frequencies and cytokine secretion by circulating T cells may reflect the stimulation with membrane-permeable activators of the protein kinase C, whereas more physiological TCR-stimulation may be required to detect functional differences in the periphery. However, when colonic T cells were stimulated with PMA/ionomoycin, increased frequencies of IFN-γ secreting T cells were found in We then evaluated whether ILC populations, previously associated with IBD pathogenesis, are differentially represented in the systemic and intestinal immune responses in patients with PSC-UC and UC. ILC have been shown to play a central role in driving intestinal inflammation in animal models of colitis, and we have previously shown that they accumulate in the inflamed intestine of patients with CD, but not those with UC. 20, 25 Interestingly, IL-22-secreting ILC can also drive colitisassociated cancer through the production of IL-22 in murine models. 21 In this study, we observed a trend towards a reduced frequency of ILC in the peripheral blood and significant accumulation of ILC in the colon of patients with PSC-UC, but not UC only, compared with controls. The ILC subset analysis in the peripheral blood may indicate that ILC1 are specifically recruited and contribute to tissue inflammation. However, a degree of plasticity has been described between ILC1 and ILC3 populations, depending on the inflammatory milieu. [37] [38] [39] ILC3 can differentiate towards ILC1 in presence of IL-12, while IL-23, IL-1β, and IL-2 can induce differentiation of ILC1 into ILC3 in vitro, with the vitamin A metabolite retinoic acid also contributing to the differentiation of ILC1 towards ILC3. The accumulation of ILC in the colon of patients with PSC-UC may contribute to tissue inflammation and increased cancer risk in these patients through cytokine production and the interaction with immune and non-immune cells. However, we appreciate that the low number of colonic samples represents a limitation of this study. Therefore, further work will be needed to confirm these observations. PSC-CD patients were not included in this study in view of previous analysis of the Oxford PSC patients' cohort, which showed a distinct clinical phenotype of patients with PSC-CD compared with PSC-UC. In particular Halliday et al. have shown that PSC-CD patients were as likely to be female as male, more commonly had small-duct PSC and less commonly progressed to cancer, liver transplantation, or death. 40 These observations were recently confirmed in a large retrospective outcome analysis. 41 Recent results of genetic studies identify PSC-IBD as a single entity, and future work should address whether there are any differences in the immune response associated with colitis in PSC-CD vs PSC-UC. In this study we have identified different T cell-and ILC-mediated immune responses in the peripheral blood and colon of patients with PSC-UC, supporting our hypothesis that PSC-associated colitis represents a distinct immunological disorder from UC. These findings are in agreement with the results of the genetic studies that have shown low genetic correlations between PSC and UC or CD and have identified a strong HLA class II association in PSC, supporting a role for T cell responses in the pathogenesis of this disease.
The identification of specific immune pathways involved in PSCassociated IBD may improve patient stratification and early diagnosis, and provide potential therapeutic targets for treatment. 
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